CompletedNCT05674929
An Open-Label, Single Dose Study in Patients With Addiction
Medication studyAges 18–64United Kingdom
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- London and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 30, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- Beckley Psytech Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05674929
- Official title
Show the full official title
An Open-Label, Phase 2a Single Dose Study in Patients With Alcohol Use Disorder
Get this study by email
Recruitment & locations
CompletedLondon
Questions about this study
Who is behind this study?
The study sponsor is Beckley Psytech Limited.
Did this study involve medication?
Yes. The study involved medication, including BPL-003.
Who was this study for?
Listed age limits: 18 years to 64 years.
Want to explore more studies?
Explore studiesRelated studies
A phase II, randomised, double-blind, placebo- controlled, multi-site, parallel group clinical trial to examine ketamine as a pharmacological treatment for alcohol dependence in an alcohol dependen...
A Study of Oral Ibogaine in Opioid Withdrawal